Clinical significance of 5-α reductase inhibitor and androgen deprivation therapy in bladder cancer incidence, recurrence, and survival: a meta-analysis and systemic review

  title={Clinical significance of 5-$\alpha$ reductase inhibitor and androgen deprivation therapy in bladder cancer incidence, recurrence, and survival: a meta-analysis and systemic review},
  author={Aram Kim and Min Seo Kim and Jae-Hak Ahn and Woo Suk Choi and Hyoung Keun Park and Hyeong-Gon Kim and Sung Hyun Paick},
  journal={The Aging Male},
  pages={971 - 978}
Abstract Purpose This study aimed to investigate the effect of androgen suppression therapy (AST), comprising a 5-α reductase inhibitor (5-ARi) and androgen deprivation therapy (ADT), on the risk of bladder cancer incidence, recurrence, and mortality. Materials and methods We used the PRISMA statement to report the methods and results of this meta-analysis. Bladder cancer incidence, recurrence, and mortality after 5-ARi treatment and ADT were assessed using risk ratios (RRs) and hazard ratios… 
Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis
Current evidence indicates that therapy with finasteride may represent a potential strategy aimed at reducing BCa incidence and that AST has a beneficial effect on the recurrence of bladder cancer.
Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies
Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease, and further studies are needed to confirm these preliminary data.
5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence
Using in vitro models for urothelial cancer, 5α-RI treatment even at supra-pharmacological doses was found to have no significant impact on the prevention of both tumorigenesis and tumor progression.
Testosterone status is not associated with bladder cancer parameters in adult male patients: results of a prospective controlled study
Testosterone level was not found to be associated with any of the categories that determine tumor aggressiveness of BCa and total testosterone levels in adult men.
Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer
Previous history of non-urothelial malignancy may lead to worse clinical outcome in patients with NMIBC, particularly current smokers, and those treated with androgen deprivation therapy had a significantly lower bladder tumor recurrence rate than their counterparts.
A high incidence of urothelial neoplasms is documents, with a male predominance and a peak incidence in the sixth decade of life, with some minor differences in international literature and reports of neighboring countries.
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Recent advances in the understanding of the molecular mechanisms of NAD -regulated physiological responses to stresses, the contribution of NAD + deficiency to various diseases via manipulating cellular communication networks and the potential new avenues for therapeutic intervention are summarized.
NAMPT and BMAL1 Are Independently Involved in the Palmitate-Mediated Induction of Neuroinflammation in Hypothalamic Neurons
It is concluded that NAMPT and BMAL1 do not interact at the transcriptional level in hypothalamic neurons, but are independently involved in the expression of inflammatory genes.


Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence
The results indicate that ADT prevents BC recurrence via the AR pathway, but not via the ERα/ERβ pathways.
Androgen deprivation therapy prevents bladder cancer recurrence
This is the first clinical study showing that ADT significantly reduces the risk of BC recurrence, and an independent prognosticator, in prostate cancer patients diagnosed with primary BC.
The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer
The aim of this study was to investigate the differential impact of androgen deprivation therapy (ADT) on subsequent risk of developing BCa in men with prostate cancer (PCa), and failed to identify any impact of ADT on therisk of developing a subsequent BCa even after stratifying according to the type of treatment.
The Genomic Alterations of 5α-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer.
5-AR could be explored as a therapeutic target for UBC with 5-ARIs after it was found that 5- AR genomic alternations were observed in 29% of UBC patients and patients with alternations had shorter disease-free survival.
Bladder Cancer Survival of Men Receiving 5&agr;‐Reductase Inhibitors
The impact of androgen deprivation and pelvic radiation on the development of bladder cancer.
The interactions among ADT, RT and UBC were investigated by performing a retrospective cohort study of elderly prostate cancer patients diagnosed between 1999-2011, using the linked SEER-Medicare database.
Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Investigation of the role of androgen receptor (AR) expression on clinicopathologic characteristics, first recurrence free survival (RFS), progressionfree survival (PFS) and multiple recurrences in non-muscle invasive bladder cancer (NMIBC) found Androgen receptor expression is associated with first and multipleRecurrence in NMIBC.